Table of Content

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in Genetic Disorders dealmaking

2.1. Introduction
2.2. Genetic Disorders partnering over the years
2.3. Genetic Disorders partnering by deal type
2.4. Genetic Disorders partnering by industry sector
2.5. Genetic Disorders partnering by stage of development
2.6. Genetic Disorders partnering by technology type
2.7. Genetic Disorders partnering by therapeutic indication

Chapter 3 –Financial deal terms for Genetic Disorders partnering

3.1. Introduction
3.2. Disclosed financials terms for Genetic Disorders partnering
3.3. Genetic Disorders partnering headline values
3.4. Genetic Disorders deal upfront payments
3.5. Genetic Disorders deal milestone payments
3.6. Genetic Disorders royalty rates

Chapter 4 – Leading Genetic Disorders deals and dealmakers

4.1. Introduction
4.2. Most active in Genetic Disorders partnering
4.3. List of most active dealmakers in Genetic Disorders
4.4. Top Genetic Disorders deals by value

Chapter 5 – Genetic Disorders contract document directory

5.1. Introduction
5.2. Genetic Disorders partnering deals where contract document available

Chapter 6 – Genetic Disorders dealmaking by therapeutic target

6.1. Introduction
6.2. Deals by Genetic Disorders therapeutic target

Appendices

Appendix 1 – Directory of Genetic Disorders deals by company A-Z 2014 to 2021
Appendix 2 – Directory of Genetic Disorders deals by deal type 2014 to 2021
Appendix 3 – Directory of Genetic Disorders deals by stage of development 2014 to 2021
Appendix 4 – Directory of Genetic Disorders deals by technology type 2014 to 2021
Further reading on dealmaking
Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from CurrentPartnering

Table of figures

Figure 1: Genetic Disorders partnering since 2014
Figure 2: Genetic Disorders partnering by deal type since 2014
Figure 3: Genetic Disorders partnering by industry sector since 2014
Figure 4: Genetic Disorders partnering by stage of development since 2014
Figure 5: Genetic Disorders partnering by technology type since 2014
Figure 6: Genetic Disorders partnering by indication since 2014
Figure 7: Genetic Disorders deals with a headline value
Figure 8: Genetic Disorders deals with upfront payment values
Figure 9: Genetic Disorders deals with milestone payment
Figure 10: Genetic Disorders deals with royalty rates
Figure 11: Active Genetic Disorders dealmaking activity– 2014 to 2021
Figure 12: Top Genetic Disorders deals by value since 2014